Pollutants and Cigarette Smoke Trigger Protein to Possibly Cause IPF

My Age Prevents Me From Participating in Clinical Trials

Next month is the five-year anniversary of when I first heard the words “idiopathic pulmonary fibrosis.” I was diagnosed by a pulmonologist at a local respiratory care center, where I’d finally been referred after 13 months of dealing with persistent shortness of breath, dry cough, and fatigue. I try…

CohBar IDs Peptide to Advance in Testing as Possible IPF Treatment

CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, based on its promising safety, efficacy, and drug-like properties in preclinical studies. The company is planning to further test this peptide — a small protein fragment — in early studies…

Peptide-coated Nanoparticles Limit Damage of IPF, Early Study Finds

Tiny particles, or nanoparticles, coated with a peptide called GSE4 prevented some features of idiopathic pulmonary fibrosis (IPF) and eased others in a rat model of this disease, scientists report. No harmful effects were associated with the use of these GSE4-loaded nanoparticles in the animals, the team added, suggesting they should…